Wockhardt Limited (WOCKPHARMA)
Press Release
Press Release - Q1FY27
- Revenue 929 Cr +26% y-y; EBITDA 188 Cr +86% y-y; PAT 107 Cr (previous year loss 108 Cr)
- Biotech operations grew 112% y-y; Emerging Market biotech up ~146% y-y
- India Branded Business revenue 156 Cr +21% y-y; UK revenue 343 Cr +10% y-y
- Emerging Markets revenue 263 Cr +64% y-y; Irish region 64 Cr +28% y-y
- New product launches: 5 international launches; biosimilars and NCE approvals
- Novel antibiotics: Zaynich approved by US FDA and India; EMA review ongoing
- Patent filings: 1 new patent this quarter; total patents held 859
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 WOCKPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add WOCKPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Wockhardt Limited
Important.
The summary above is generated automatically from Wockhardt Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.